Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex, class II, DP beta 1 pseudogene is a genomic sequence on human chromosome 6 that resembles the functional gene HLA-DPB1 but lacks the ability to encode a functional protein. HLA-DPB1 is part of the human leukocyte antigen (HLA) complex, encoding a subunit of the class II major histocompatibility complex (MHC) molecules that play a pivotal role in the adaptive immune response by presenting extracellular peptides to CD4+ T cells. In contrast, the pseudogene version does not produce a functional DP beta chain and is not implicated in antigen presentation or immune signaling. It is a remnant of genomic evolution with no current therapeutic, diagnostic, or direct biological relevance. For structured annotation, this pseudogene should be clearly distinguished from its protein-coding counterpart (HLA-DPB1); only the latter would be relevant in drug discovery, immunity, disease association, and clinical biomarker contexts.
None. Mechanisms of action for drugs are not relevant for pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex, class II, DP beta 1 pseudogene (No widely recognized abbreviation; HLA-DPB1 is used for the functional gene, but for the pseudogene, none is canonical.).